Information Provided By: 
Fly News Breaks for January 2, 2018
BCRX
Jan 2, 2018 | 07:01 EDT
As reported earlier, RBC Capital analyst Brian Abrahams upgraded BioCryst to Outperform from Sector Perform and raised his price target to $8 from $6. Abrahams says the lead drug BCX7353 showed a clear reduction in hereditary angioedema attacks in its phase 2 study, while its lack of dose dependence is "legitimately explainable by misidentification of GI side effects at the higher doses". The analyst adds that the recent FDA precedent also implies a "relatively low bar for approvals of drugs to treat rare, potentially fatal diseases".
News For BCRX From the Last 2 Days
There are no results for your query BCRX
